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Abstract 
Pools of factor XIII (FXIII) exist in the plasma and within the cytoplasm of 
hematopoietic cells, including platelets.  The functions of the cellular form, FXIII-A, 
have been assumed to be intracellular in nature, as the protein lacks a signal 
sequence for its release.  Mounting evidence now suggests that platelet FXIII-A 
modulates hemostasis by several different mechanisms.  In this condensed review 
we discuss recent advances in our understanding of the novel intracellular and 
extracellular functions of platelet FXIII-A.     
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Background 
Factor XIIIa (FXIIIa; E.C. 2.3.2.13) is a glutaminyl-peptide γ-glutamyl transferase that 
functions to stabilize fibrin against mechanical stress and proteolytic degradation.  
FXIII circulates in plasma as a tetramer composed of two pairs of non-identical 
subunits; the A2 subunits, containing the active site and the carrier B2 subunits [1]. 
Cleavage of FXIII-A2B2 by thrombin in the presence of Ca2+ permits dissociation of 
the carrier B subunits and exposure of the active site cysteine generating an active 
transglutaminase enzyme, FXIIIa [2, 3]. FXIIIa is unique in its classification as a 
coagulation factor, as it is the only non-proteolytic enzyme within the cascade.  
 
Cross-linking of fibrin and inhibitors by FXIIIa 
Activated FXIII crosslinks substrates via formation of ε-(γ-glutamyl) lysyl isopeptide 
bonds [4].  Numerous factor XIII substrates have now been identified, including a 
number of platelet-derived proteins such as actin, glycoprotein 1b and other 
cytoskeletal elements [5-10].  This review will centre on cross-linking of fibrin and 
inhibitors of fibrinolysis.  The initial cross-links that form in fibrin arise rapidly 
between γ-chains of neighbouring fibrin molecules [11] with subsequent high 
molecular weight polymers forming upon α-chain cross-linking [3, 12].  Cross-linking 
has a direct impact on the rheological properties of fibrin, enhancing clot rigidity and 
stabilizing against mechanical stress [13, 14].  FXIIIa also cross-links several 
inhibitors of fibrinolysis to fibrin, namely α2-antiplasmin (α2AP) [15], thrombin 
activatable fibrinolysis inhibitor [16] and plasminogen activator inhibitor-2 [17].  The 
influence of cross-linking on inhibition of fibrinolysis is difficult to visualise using 
conventional in vitro models, such as clot lysis.  However, using a flow-based model 
we were able to demonstrate a direct effect of FXIIIa in down-regulating thrombus 
lysis [18].  α2AP is the principal fast acting inhibitor of the fibrinolytic protease 
plasmin [19] and is cross-linked via Gln-2 to Lys-303 of the Aα chain of fibrin(ogen) 
by FXIIIa [20].   Neutralization or deficiency of α2AP dramatically impacts the 
susceptibility of thrombi to fibrinolysis [15, 21, 22].  Using flow we revealed that the 
antifibrinolytic function of FXIIIa is exclusively mediated via cross-linking of α2AP to 
fibrin, with thrombi that lack either FXIII or α2AP lysing at strikingly similar rates [23].    
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Cellular FXIII-A 
FXIII exists in a cellular form (FXIII-A) within the cytoplasm of several haematopoietic 
cells including platelets [1, 24-29] megakaryocytes [30], monocytes [31, 32], 
circulating [33] and tissue macrophages [32].  Platelets contain an abundance of 
FXIII [34] predominantly within their cytoplasm, as a homodimer of FXIII-A [26, 27], 
however a small pool of the A2B2 form is reported to exist within α-granules [26, 35].  
The source of α-granule FXIII is plasmatic, as the A2B2 form circulates bound to 
fibrinogen and both are simultaneously endocytosed by platelets [35]. Early studies 
indicated that platelet FXIII-A is retained in the cytoplasm following activation and is 
not detectable in the platelet secretome [36].  FXIII-A does not contain an identifiable 
endoplasmic reticulum (ER) signalling sequence and is excluded from the ER-Golgi 
pathway in nucleated cells [37].  However, it has been found to be directed toward 
the plasma membrane in association with Golgi vesicles in monocyte-macrophages 
[38].  Due to the lack of ER-leader sequence FXIII-A cannot be targeted to α-
granules in nascent platelets during de novo synthesis in megakaryocytes.  This has 
led to the assumption that the functions of platelet FXIII-A are intracellular and 
distinct from the role of the plasma A2B2 form of FXIII in hemostasis.   
 
Intracellular roles of platelet FXIII-A 
Activation of platelets by conventional agonists generates a rapid spike in 
intracellular Ca2+ [39], where concentrations above 2 mM [40] enable non-proteolytic 
activation of FXIII-A [41].  Platelet FXIII-A has been implicated in several 
intracellular-mediated processes, including clot retraction.  This dynamic process 
involves the reorganisation of proteins and structures at intra- and extracellular level 
and bidirectional signalling via the integrin, αIIbβ3.  Initially, inside-out signalling 
induces a conformational change in αIIbβ3 allowing it to bind extracellular 
fibrin(ogen) [42].  Once in place the ligand triggers αIIbβ3-mediated outside-in 
signalling [43] which connects to the actin cytoskeleton via talin [44].  The actin 
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cytoskeleton then effectively acts as a winch to reel in the fibrin coupled to the 
extracellular portion of the receptor via platelet pseudopodia. Plasma FXIII also 
facilitates clot retraction by cross-linking extracellular fibrin, thereby increasing 
network rigidity, and by enhancing platelet spreading [45].  Clot retraction is 
significantly impaired in the absence of platelet FXIII-A transglutaminase activity [46, 
47].  Platelet FXIII-A also cross-links intracellular cytoskeletal proteins [6-10] and 
regulates reorganisation of the activated platelet cytoskeleton and αIIbβ3 via 
sphingomyelin-rich lipid rafts, which act as the axis between intracellular and 
extracellular clot retraction mechanisms [46]. 
During thrombus formation different subpopulations of platelets arise [48] which 
display distinct phenotypic characteristics and play diverse roles within the 
microenvironment of the thrombus.  Adherent platelets, with activated αIIbβ3, 
facilitate platelet-platelet interaction and binding to fibrin thereby augmenting 
thrombus stability [48].  Phosphatidylserine (PS)-exposing procoagulant platelets 
promote thrombin generation and further fibrin formation [49].  Platelet FXIII-A and 
calpain have been implicated in the adhesive capacity of αIIbβ3 in procoagulant 
platelets thereby regulating thrombus size [50].  Formation of the highly procoagulant 
‘coated’ platelets is also regulated by transglutaminase activity, which cross-links α-
granule proteins, such as platelet factor V, to serotonin on the activated platelet 
surface [51, 52].  Jobe et al [53] demonstrated that FXIII was dispensable for coated 
platelet formation in mice. Interestingly, these FXIIIA-/- mice demonstrated increased 
transglutaminase activity in platelet lysates, suggestive of a compensatory 
mechanism by another transglutaminase.  Recent findings confirmed the contribution 
of tranglutaminase and highlighted a role for the integrin αIIbβ3 in coated platelet 
formation and in subsequent platelet-dependent fibrin formation [54]. 
Extracellular functions of platelet FXIII-A 
Early studies on the antifibrinolytic function of platelet FXIII-A identified that platelets 
mediated stabilization of clots [55], induced high molecular weight γ-dimer and α-
polymer formation [55-59] and cross-linked α2AP to fibrin [56, 57].  Despite these 
studies implicating platelet FXIII-A in extracellular hemostasis events there was no 
direct evidence illustrating its release from platelets.  Our recent work has shown that 
platelet FXIII-A is undetectable in the platelet secretome, as previously reported [36], 
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but is externalized onto the outer membrane of activated platelets [60].  Intriguingly, 
the distribution of FXIII-A on the activated platelet membrane depends on the 
subpopulation of platelets; with PS-negative, adherent platelets displaying a diffuse 
distribution, while PS-positive, procoagulant platelets expose FXIII-A in a single 
protruding ‘cap’ (Figure 1) [60]. These ‘caps’ have previously been shown to bind 
fibrinogen [61] and we have shown that they harbour other proteins including 
plasminogen and PAI-1 [62]. The reduction in the adhesive ability of αIIbβ3 by FXIII-
A [50] combined with the clustering of fibrinolytic proteins in the ‘caps’ of these 
procoagulant platelets suggest they may function in regulating thrombus stability.  
We found that thrombi formed from FXIII-deficient plasma were stabilized by the 
addition of platelets in a transglutaminase-dependent manner [60].  In order to 
protect against fibrinolysis functional α2AP was required, indicating that platelet 
FXIII-A actively participates in extracellular cross-linking reactions [60]. 
Surface exposure and cross-linking by platelet FXIII-A was only evident following 
platelet activation and coincided with translocation from the cytoplasm to the outer 
leaflet of the membrane [60].  The exact signalling mechanisms involved are still to 
be defined, but it is likely that the previously described interactions of FXIII-A with 
intracellular clot retraction machinery [6-10], lipid rafts [46] and αIIbβ3 are crucial to 
its externalization upon platelet activation (Figure 2).  FXIII-A activity was also 
evident with thrombin receptor activation peptide 6 (TRAP-6)-mediated platelet 
activation, confirming that activation from the protransglutaminase to functional 
transglutaminase does not require thrombin and arises from the spike in intracellular 
Ca2+ upon activation.  Interestingly, inhibition of fibrin polymerisation with Gly-Pro-
Arg-Pro, or activation of platelets by TRAP-6 in place of thrombin reduced the 
number of FXIII-A-positive platelets.  These data imply that platelet-bound fibrin 
participates in the retention of FXIII-A and possibly serves as an anchor-point for 
transfer of FXIII-A into the adjacent fibrin network allowing participation in 
extracellular cross-linking reactions [60].  It has been shown that FXIII-A binds to the 
αC domain (residues 389-402) of fibrin(ogen) via both its active site [63] and its 
activation peptide cleft thereby promoting crosslinking of fibrin and α2AP [64].  It is 
plausible that upon platelet activation FXIII-A will bind to platelet-bound fibrin via 
these two sites.  In accordance with this the fibrin network immediately adjacent to 
the surface of activated platelets is extremely resistant to fibrinolysis [62, 65-68].   
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The antifibrinolytic function of platelet FXIII-A may be central in stabilizing thrombi in 
certain situations, such as during surgery when plasma FXIII-A2B2 levels rapidly 
decline [69] or following cardiopulmonary bypass with extracorporeal circuit.  
Acquired FXIII deficiency can also occur in the case of major trauma where plasma 
FXIII-A2B2 levels deplete to around 30-35% of normal [70]. FXIII-B subunit deficiency 
leads to dramatic reduction in FXIII-A concentration in plasma, due to its instability 
[71-73], however platelet FXIII-A levels are normal [72, 74].  FXIII-B deficiency is less 
severe than FXIII-A deficiency [71, 75]  which is attributed to remaining circulating 
FXIII-A in plasma.  Our results indicate that platelet FXIII-A may contribute to 
thrombus stabilization in these situations. We show that when plasma FXIII-A2B2 is 
below 20% of normal the antifibrinolytic effect of platelet FXIII-A becomes apparent 
[60]. 
 
Concluding remarks 
Clearly the role of platelet FXIII-A has been markedly underestimated with a 
mounting body of evidence highlighting its importance in modulating platelet 
phenotype [50-52], facilitating the intracellular elements of clot retraction [46, 47] and 
mediating extracellular cross-linking reactions [60].  These reports illustrate that 
FXIII-A has diverse and crucial functions in thrombus formation and stability.  Further 
work is required to tease out the importance of platelet FXIII-A in relation to plasma-
derived FXIII and whether these enzymes play functionally distinct but overlapping 
roles in hemostasis.  There are also multiple questions related to the signalling 
events involved in the externalisation of cytoplasmic FXIII-A on the stimulated 
platelet membrane and its ability to actively diffuse into the surrounding fibrin 
network; as suggested by its ability to cross-link extracellular substrates (Figure 2).  
These observations and insights into the functions of platelet FXIII-A underscore the 
seamless transition between intracellular and extracellular events that modulate 
thrombus formation and stability in vivo. 
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Figure Legends 
Figure 1: Activated platelets expose FXIII-A on their membrane surface. 
Washed platelets (5 x 107/ml) stained using FITC-labelled anti-FXIII-A antibody 
(green) and Alexa-fluor®647 Annexin-V to detect phosphatidylserine (red). Top 
panel - PS and FXIII-A co-expressing platelets stimulated by 20 µg/ml collagen/ 20 
µM TRAP-6 or 20 µg/ml collagen /100 nM thrombin. Bottom Panel - PS-negative 
platelets stimulated with 20 µg/ml collagen/ 20 µM TRAP-6 or 20 µg/ml collagen /100 
nM thrombin. Scale bars represent 5 µM. Representative experiments of n=4.Images 
obtained by a Zeiss LSM710 confocal microscope with 63x 1.40 oil immersion 
objective and analyzed using Zen 2012 software [60].  
Figure 2: Schematic representation of interactions between platelets and FXIII.  
Platelet activation results in the polymerization of intracellular actin and induces 
conformational changes in integrin αIIbβ3 mediated via inside-out signalling.  
Fibrin(ogen) is then able to bind αIIbβ3 and outside-in signalling allows the binding of 
αIIbβ3 to polymerised actin via talin.  Platelet contractile machinery then pulls on the 
fibrin network via platelet pseudopods resulting in the compaction of the clot and 
extrusion of excess non-cross-linked material. Platelet FXIII-A plays a major role in 
the intracellular facilitation of clot retraction by cross-linking cytoskeletal proteins and 
facilitating reorganisation of the αIIbβ3 and the platelet cytoskeleton via lipid rafts. 
Plasma FXIII enhances clot retraction extracellularly by cross-linking fibrin thereby 
providing further rigidity to the network and allowing enhanced platelet spreading. 
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